CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $3.49 billion. The enterprise value is $2.82 billion.

Market Cap	3.49B
Enterprise Value	2.82B

Important Dates

The last earnings date was Friday, November 14, 2025, before market open.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 80.67 million shares outstanding. The number of shares has increased by 60.24% in one year.

Current Share Class	80.67M
Shares Outstanding	80.67M
Shares Change (YoY)	+60.24%
Shares Change (QoQ)	+0.66%
Owned by Insiders (%)	0.81%
Owned by Institutions (%)	95.22%
Float	65.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1,606.64
Forward PS	n/a
PB Ratio	4.93
P/TBV Ratio	5.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,297.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 22.79, with a Debt / Equity ratio of 0.01.

Current Ratio	22.79
Quick Ratio	22.30
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -24.74% and return on invested capital (ROIC) is -18.28%.

Return on Equity (ROE)	-24.74%
Return on Assets (ROA)	-17.56%
Return on Invested Capital (ROIC)	-18.28%
Return on Capital Employed (ROCE)	-25.75%
Revenue Per Employee	$19,239
Profits Per Employee	-$1.34M
Employee Count	113
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+20.58%
50-Day Moving Average	41.66
200-Day Moving Average	30.19
Relative Strength Index (RSI)	53.40
Average Volume (20 Days)	867,979

Short Selling Information

The latest short interest is 13.21 million, so 16.37% of the outstanding shares have been sold short.

Short Interest	13.21M
Short Previous Month	12.48M
Short % of Shares Out	16.37%
Short % of Float	20.18%
Short Ratio (days to cover)	14.15

Income Statement

In the last 12 months, CG Oncology had revenue of $2.17 million and -$151.48 million in losses. Loss per share was -$2.03.

Revenue	2.17M
Gross Profit	-112.89M
Operating Income	-180.12M
Pretax Income	-151.48M
Net Income	-151.48M
EBITDA	-179.53M
EBIT	-180.12M
Loss Per Share	-$2.03

Full Income Statement

Balance Sheet

The company has $680.26 million in cash and $7.24 million in debt, giving a net cash position of $673.02 million or $8.34 per share.

Cash & Cash Equivalents	680.26M
Total Debt	7.24M
Net Cash	673.02M
Net Cash Per Share	$8.34
Equity (Book Value)	687.64M
Book Value Per Share	8.78
Working Capital	665.26M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$116.79 million and capital expenditures -$336,000, giving a free cash flow of -$117.13 million.

Operating Cash Flow	-116.79M
Capital Expenditures	-336,000
Free Cash Flow	-117.13M
FCF Per Share	-$1.45

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-8,285.33%
Pretax Margin	-6,967.99%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-60.24%
Shareholder Yield	-60.24%
Earnings Yield	-4.34%
FCF Yield	-3.35%

Analyst Forecast

The average price target for CG Oncology is $67.64, which is 56.21% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$67.64
Price Target Difference	56.21%
Analyst Consensus	Strong Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	223.93%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 29.99 and a Piotroski F-Score of 3.

Altman Z-Score	29.99
Piotroski F-Score	3